Overview

Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of 50, 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with plaque psoriasis
Phase:
Phase 2
Details
Lead Sponsor:
Alza Corporation, DE, USA